# AstraZeneca Plc completes acquisition of Amolyt Pharma

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-completes-acquisition-of-amolyt-pharma/4121164969
- Published: 2024-07-15T07:16:44+01:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
has announced the successful completion of the acquisition of Amolyt Pharma, a clinical-
stage biotechnology company focused on developing novel treatments for rare endocrine
diseases.

The acquisition bolsters the Alexion, AstraZeneca Rare Disease late-stage pipeline
and expands on its bone metabolism franchise with the notable addition of eneboparatide(
AZP-3601), a Phase III investigational therapeutic peptide with a novel mechanism
of action designed to meet key therapeutic goals for hypoparathyroidism. In patients
with hypoparathyroidism, a deficiency in parathyroid hormone (PTH) production results
in significant dysregulation of calcium and phosphate, which can lead to life-altering
symptoms and complications, including chronic kidney disease.^(1)  This programme,
together with Amolyt’s talent, expertise and earlier pipeline, will enable Alexion’s
expansion into rare endocrinology.

**Financial considerations**

Under the terms of the definitive agreement, AstraZeneca has acquired all of Amolyt
Pharma’s outstanding shares for a total consideration of up to $1.05 billion, on
a cash and debt free basis. This includes $800 million upfront at deal closing, 
plus the right for Amolyt Pharma’s shareholders to receive an additional contingent
payment of $250 million payable upon achievement of a specified regulatory milestone.
AstraZeneca looks forward to welcoming the employees of Amolyt Pharma.

Share on:
